ADAMTS13 and VWF levels in relation to MI
| . | No. of patients . | No. of controls . | OR 1 (95% CI)* . | OR 2 (95% CI)† . | OR 3 (95% CI)‡ . |
|---|---|---|---|---|---|
| ADAMTS13 level | |||||
| 3%-85% | 94 | 155 | 1§ | 1§ | 1§ |
| 86%-97% | 143 | 151 | 1.53 (1.08-2.16) | 1.54 (1.09-2.18) | 1.53 (1.08-2.16) |
| 98%-110% | 153 | 149 | 1.63 (1.16-2.30) | 1.64 (1.16-2.32) | 1.67 (1.18-2.36) |
| 111%-433% | 144 | 152 | 1.50 (1.06-2.12) | 1.48 (1.05-2.10) | 1.56 (1.10-2.22) |
| VWF level | |||||
| 40%-97% | 103 | 152 | 1§ | 1§ | 1§ |
| 98%-124% | 123 | 153 | 1.28 (0.90-1.81) | 1.28 (0.90-1.81) | 1.24 (0.87-1.76) |
| 125%-159% | 165 | 153 | 1.77 (1.26-2.49) | 1.77 (1.26-2.49) | 1.64 (1.16-2.32) |
| 160%-900% | 143 | 149 | 1.63 (1.15-2.33) | 1.64 (1.15-2.33) | 1.44 (1.00-2.07) |
| . | No. of patients . | No. of controls . | OR 1 (95% CI)* . | OR 2 (95% CI)† . | OR 3 (95% CI)‡ . |
|---|---|---|---|---|---|
| ADAMTS13 level | |||||
| 3%-85% | 94 | 155 | 1§ | 1§ | 1§ |
| 86%-97% | 143 | 151 | 1.53 (1.08-2.16) | 1.54 (1.09-2.18) | 1.53 (1.08-2.16) |
| 98%-110% | 153 | 149 | 1.63 (1.16-2.30) | 1.64 (1.16-2.32) | 1.67 (1.18-2.36) |
| 111%-433% | 144 | 152 | 1.50 (1.06-2.12) | 1.48 (1.05-2.10) | 1.56 (1.10-2.22) |
| VWF level | |||||
| 40%-97% | 103 | 152 | 1§ | 1§ | 1§ |
| 98%-124% | 123 | 153 | 1.28 (0.90-1.81) | 1.28 (0.90-1.81) | 1.24 (0.87-1.76) |
| 125%-159% | 165 | 153 | 1.77 (1.26-2.49) | 1.77 (1.26-2.49) | 1.64 (1.16-2.32) |
| 160%-900% | 143 | 149 | 1.63 (1.15-2.33) | 1.64 (1.15-2.33) | 1.44 (1.00-2.07) |
Levels of ADAMTS13 and VWF are depicted as quartiles, and OR was determined using the lowest quartiles as the reference groups. For patients, total n = 534; for total controls, n = 607.
Adjusted for age.
Adjusted for age, VWF, or ADAMTS13 as continuous variable.
Adjusted for age, log-transformed CRP.
Reference group.